Print

Pfizer Inc. (PFE): Adding Inspra(R) (eplerenone) To Standard Therapy Reduces The Incidence Of New Onset Atrial Fibrillation/Flutter (AF/F) In Patients With Systolic Heart Failure, Sub-Analysis Shows  
5/23/2011 9:23:25 AM

Pfizer Inc. (NYSE: PFE) today announced results from a pre-specified sub-analysis1 of the EMPHASIS-HF trial2 which showed that Inspra® (eplerenone), added to standard recommended therapy, statistically significantly reduced the incidence of new onset atrial fibrillation or flutter (AF/F) in patients with systolic heart failure and mild symptoms, compared with placebo plus standard therapy. This analysis was a pre-specified secondary endpoint in the EMPHASIS-HF study, the results of which were presented to physicians attending the European Society of Cardiology Heart Failure Congress in Gothenburg, Sweden.
//-->